Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




New Tool Exposes Hidden Cancer DNA Changes Driving Treatment Resistance

By LabMedica International staff writers
Posted on 07 Aug 2025

Some of the most damaging genetic changes in cancer are also the most difficult to detect. More...

Structural alterations buried deep within a tumor's DNA can drive aggressive growth and evade traditional testing methods, especially when tumor samples are small or degraded. These hidden genomic changes can interfere with accurate diagnosis and hinder the development of effective treatment strategies. Now, researchers have developed a new tool that exposes previously invisible layers of genomic instability and provides insights into how tumors might behave and respond to treatment.

The new tool, named BACDAC, has been developed by researchers at Mayo Clinic (Rochester, MN, USA) to identify signs of genomic instability using whole-genome DNA sequencing, even in low-purity or low-coverage tumor samples. At the heart of BACDAC's functionality is the concept of ploidy, or the number of complete chromosome sets in a cell. While healthy cells contain two sets of chromosomes, cancer cells often exhibit abnormal changes such as whole-genome doubling, a phenomenon that disrupts chromosomal balance and enables uncontrolled tumor growth.

BACDAC also features a unique visual interface known as the Constellation Plot, which provides a clear and intuitive summary of a tumor’s genomic landscape, helping pathologists and researchers determine whether a tumor’s chromosomes are stable or disrupted. The researchers validated BACDAC by applying it to over 650 tumors across 12 different cancer types. The findings, published in the journal Genome Biology, show that the tool successfully detected indicators of whole-genome doubling, a structural abnormality frequently associated with aggressive tumors and resistance to therapy.

The team now plans to further validate BACDAC and develop it into a clinically deployable diagnostic platform. By offering a clearer view of complex genomic alterations, this tool could inform more personalized cancer treatments and improve outcomes for patients facing hard-to-treat cancers.

"This tool lets us see a layer of the genome that's been invisible until now. We've spent decades studying the biology of genomic instability. This is the first time we've been able to translate that knowledge into a tool that works at scale, " said George Vasmatzis, Ph.D., lead author of the study.

Related Links:
Mayo Clinic


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.